Gilead revised full-year product sales guidance to $30.1–$30.4 billion versus $30.06 billion expected and adjusted EPS to −$0.30–−$0.65, cutting Veklury revenue outlook to $300 million from $600 million.
FirstSquawk08/05, 03:08 AM
- $30.1 BLN-$30.4 BLN
- $30.06 BLN
- 30C-65C
- $300 MLN
Figures as quoted by FirstSquawk
Related assets
Coming up for GILD
Explore next
Latest GILD news
Jin1008/14, 09:47 PM
FirstSquawk08/05, 03:08 AM
Bloomberg07/29, 06:35 PM